

FOI2907

25<sup>th</sup> February 2025

## FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

---

**Q1. For patients treated by the dermatology department with Dupilumab in the latest four months (September to December 2024), could you please tell us:**

**a. how many patients were treated in the previous 4-month period (May to August 2024) with Dupilumab?**

**Response:**

122

**b. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?**

**Response:**

24

**c. how many patients were treated in the previous 4-month period (May to August 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?**

**Response:**

Data not held – supplied in Primary Care

**d. how many patients were treated in the previous 4-month period (May to August 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)**

**Response:**

Data not held in Pharmacy nor centrally held. In order to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

**Q2. For patients treated by the dermatology department with Dupilumab in the four months from May to August 2024, could you please let us:**

**a. how many patients were treated in the subsequent 4-month period (September to December 2024) with Dupilumab?**

**Response:**

127

**b. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?**

**Response:**

33

**c. how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?**

**Response:**

Data not held – supplied in Primary Care

**d. how many patients were treated in the subsequent 4-month period (September to December 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)**

**Response:**

Data not held in Pharmacy nor centrally held. In order to provide this information a significant manual trawl of records from a number of sources is required. The cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information, it would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Email: [foi.team@southerntrust.hscni.net](mailto:foi.team@southerntrust.hscni.net)